These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

495 related articles for article (PubMed ID: 8528099)

  • 1. Prodrugs in cancer chemotherapy.
    Connors TA; Knox RJ
    Stem Cells; 1995 Sep; 13(5):501-11. PubMed ID: 8528099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prodrugs in Cancer Chemotherapy.
    Knox RJ; Connors TA
    Pathol Oncol Res; 1997; 3(4):309-324. PubMed ID: 11173653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The choice of prodrugs for gene directed enzyme prodrug therapy of cancer.
    Connors TA
    Gene Ther; 1995 Dec; 2(10):702-9. PubMed ID: 8750009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strategies for enzyme/prodrug cancer therapy.
    Xu G; McLeod HL
    Clin Cancer Res; 2001 Nov; 7(11):3314-24. PubMed ID: 11705842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates.
    Wallace PM; Senter PD
    Methods Find Exp Clin Pharmacol; 1994 Sep; 16(7):505-12. PubMed ID: 7885077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancement of antibody-directed enzyme prodrug therapy in colorectal xenografts by an antivascular agent.
    Pedley RB; Sharma SK; Boxer GM; Boden R; Stribbling SM; Davies L; Springer CJ; Begent RH
    Cancer Res; 1999 Aug; 59(16):3998-4003. PubMed ID: 10463598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody-directed enzyme prodrug therapy with the T268G mutant of human carboxypeptidase A1: in vitro and in vivo studies with prodrugs of methotrexate and the thymidylate synthase inhibitors GW1031 and GW1843.
    Wolfe LA; Mullin RJ; Laethem R; Blumenkopf TA; Cory M; Miller JF; Keith BR; Humphreys J; Smith GK
    Bioconjug Chem; 1999; 10(1):38-48. PubMed ID: 9893962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of oxazaphosphorines by cytochrome P450: application to gene-directed enzyme prodrug therapy for cancer.
    Roy P; Waxman DJ
    Toxicol In Vitro; 2006 Mar; 20(2):176-86. PubMed ID: 16293390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prodrugs for antibody- and gene-directed enzyme prodrug therapies (ADEPT and GDEPT).
    Niculescu-Duvaz I; Friedlos F; Niculescu-Duvaz D; Davies L; Springer CJ
    Anticancer Drug Des; 1999 Dec; 14(6):517-38. PubMed ID: 10834273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody-directed enzyme prodrug therapy (ADEPT) for cancer.
    Bagshawe KD
    Expert Rev Anticancer Ther; 2006 Oct; 6(10):1421-31. PubMed ID: 17069527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Engineering a thermostable human prolyl endopeptidase for antibody-directed enzyme prodrug therapy.
    Heinis C; Alessi P; Neri D
    Biochemistry; 2004 May; 43(20):6293-303. PubMed ID: 15147213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enzyme-catalyzed activation of anticancer prodrugs.
    Rooseboom M; Commandeur JN; Vermeulen NP
    Pharmacol Rev; 2004 Mar; 56(1):53-102. PubMed ID: 15001663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent developments in gene-directed enzyme prodrug therapy (GDEPT) for cancer.
    Niculescu-Duvaz I; Cooper RG; Stribbling SM; Heyes JA; Metcalfe JA; Springer CJ
    Curr Opin Mol Ther; 1999 Aug; 1(4):480-6. PubMed ID: 11713763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic gene-directed enzyme prodrug therapy of hepatocellular carcinoma using a targeted adenovirus armed with carboxypeptidase G2.
    Schepelmann S; Hallenbeck P; Ogilvie LM; Hedley D; Friedlos F; Martin J; Scanlon I; Hay C; Hawkins LK; Marais R; Springer CJ
    Cancer Res; 2005 Jun; 65(12):5003-8. PubMed ID: 15958540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anticancer Drug Development: The Way Forward.
    Connors T
    Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined adenovirus-mediated nitroreductase gene delivery and CB1954 treatment: a well-tolerated therapy for established solid tumors.
    Djeha AH; Thomson TA; Leung H; Searle PF; Young LS; Kerr DJ; Harris PA; Mountain A; Wrighton CJ
    Mol Ther; 2001 Feb; 3(2):233-40. PubMed ID: 11237680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suicide gene therapy using E. coli beta-galactosidase.
    Farquhar D; Pan BF; Sakurai M; Ghosh A; Mullen CA; Nelson JA
    Cancer Chemother Pharmacol; 2002 Jul; 50(1):65-70. PubMed ID: 12111114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prodrug activation enzymes in cancer gene therapy.
    Aghi M; Hochberg F; Breakefield XO
    J Gene Med; 2000; 2(3):148-64. PubMed ID: 10894261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody-directed enzyme prodrug therapy: a promising approach for a selective treatment of cancer based on prodrugs and monoclonal antibodies.
    Tietze LF; Krewer B
    Chem Biol Drug Des; 2009 Sep; 74(3):205-11. PubMed ID: 19660031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rabbit cytochrome P450 4B1: A novel prodrug activating gene for pharmacogene therapy of hepatocellular carcinoma.
    Mohr L; Rainov NG; Mohr UG; Wands JR
    Cancer Gene Ther; 2000 Jul; 7(7):1008-14. PubMed ID: 10917203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.